InsidersTradesSigma
Track the Avanos Medical, INC. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Avanos Medical, INC. has logged 148 public disclosures. Market capitalisation: €1.2bn. The latest transaction was filed on 28 July 2026 (Disposition). Among the most active insiders: Hurley John Joseph. Every trade is openly available.
148
Insider Decl.
n/a
Thresholds
€261,910
3 ops.
Buy Volume
€30m
15 ops.
Sell Volume
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,105 of 29,063 companies
36.5
score / 100
Value39
Quality34
FCF yld3.7%
Earn yld-6.2%
EV/EBITDA·
ROE-9.2%
Gross mgn50%
Net mgn-10%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 July 2026
Declarations148 total
55,741 shares@ US$25.000.12% mcap48.6% of flowCommon StockSEC:0001606498-26-000112:0
40,000 shares@ US$25.000.085% mcap31.2% of flowCommon StockSEC:0001606498-26-000105:0
444,730 shares0Common StockSEC:0001606498-26-000110:1
96,121 shares0Common StockSEC:0001606498-26-000111:1
54,886 shares0Common StockSEC:0001606498-26-000112:1
4,817 shares@ US$25.000.010% mcap100.0% of flowCommon StockSEC:0001606498-26-000107:0
54,640 shares@ US$25.000.12% mcap94.8% of flowCommon StockSEC:0001606498-26-000108:0
322,194 shares@ US$25.000.69% mcap41.4% of flowCommon StockSEC:0001606498-26-000110:0
444,730 shares@ US$25.000.95% mcap57.1% of flowCommon StockSEC:0001606498-26-000110:2
79,590 shares@ US$25.000.17% mcap62.1% of flowCommon StockSEC:0001606498-26-000105:1
13,811 shares@ US$25.000.029% mcap100.0% of flowCommon StockSEC:0001606498-26-000106:0
50,090 shares@ US$25.000.11% mcap99.2% of flowCommon StockSEC:0001606498-26-000109:0
135,596 shares@ US$25.000.29% mcap55.9% of flowCommon StockSEC:0001606498-26-000111:0
96,121 shares@ US$25.000.20% mcap39.6% of flowCommon StockSEC:0001606498-26-000111:2
54,886 shares@ US$25.000.12% mcap47.8% of flowCommon StockSEC:0001606498-26-000112:2
4,264 shares@ US$24.640.0088% mcap100.0% of flowCommon StockSEC:0001606498-26-000058:0
4,228 shares@ US$24.640.0087% mcap39.7% of flowCommon StockSEC:0001606498-26-000059:0
21,194 shares@ US$14.530.025% mcap100.0% of flowCommon StockSEC:0001606498-26-000052:0
29,481 shares0Common StockSEC:0001606498-26-000040:0
15,886 shares0Common StockSEC:0001606498-26-000042:0
101,341 shares0Common StockSEC:0001606498-26-000033:0
101,341 shares0Common StockSEC:0001606498-26-000038:0
15,886 shares0Common StockSEC:0001606498-26-000035:0
29,481 shares0Common StockSEC:0001606498-26-000031:0
15,886 shares0Common StockSEC:0001606498-26-000023:0
25 of 148 declarations
关于 Avanos Medical, INC.
Avanos Medical, Inc.（股票代码：AVNS）是一家在美国纽约证券交易所上市的美国医疗技术公司。该公司专注于支持肠内营养、疼痛管理和术后康复的专业医疗设备。其投资概况是一家利基医疗技术公司：Avanos 更多关注临床导向的差异化产品，这些产品用于易用性、安全性以及患者预后至关重要的工作流程，而非广泛的、商品化的医院用品。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1606498/000110465925024289/tm253661d2_ars.pdf?utm_source=openai)） Avanos 的现代公司历史可追溯到 2014 年 Halyard Health 的分拆，并于 2018 年更名为 Avanos Medical。公司总部位于佐治亚州阿尔法利塔，这使其在美国东南部拥有明确的运营基地，同时保持国际业务。Avanos 将自己定位为一家全球性企业，业务范围覆盖北美、欧洲、中东和非洲、亚太地区以及拉丁美洲。（[avanos.com](https://avanos.com/about-avanos/?utm_source=openai)） 该业务围绕两个主要特许经营权组织：专业营养系统和疼痛管理与康复。专业营养系统涵盖肠内营养和药物准备/输送产品，用于从新生儿重症监护室和儿科环境到成人长期护理的整个护理连续体。疼痛管理与康复提供非阿片类解决方案，用于慢性疼痛和术后疼痛，包括射频消融、冷压和便携式疼痛泵。主要品牌名称包括 MIC-KEY、CORPAK、COOLIEF、ambIT 和 GAME READY，这些品牌对于公司的临床定位至关重要。（[avanos.com](https://avanos.com/our-brands/?utm_source=openai)） 从竞争角度来看，Avanos 占据了医疗技术市场的专业细分领域，与大型设备制造商竞争，但通过临床专业化、有针对性的产品创新以及对医疗保健专业人员和患者的强大支持来实现差异化。公司还强调制造集成和产品培训/支持，这在需要可靠性和一致性能的程序中可能很重要。（[avanos.com](https://avanos.com/wp-content/uploads/2025/04/Avanos-2024-Corporate-Citizenship-Report-vF.pdf?utm_source=openai)） 最近的战略发展表明了投资组合优化策略。2023 年，Avanos 同意收购 Diros Technology，以加强其射频疼痛治疗产品，增加旨在补充 COOLIEF 平台的技术。同年，它将其呼吸健康业务出售给 SunMed，从而进一步聚焦于其认为具有更好战略契合度的特许经营权。因此，对于投资者而言，AVNS 仍然是一家在纽约证券交易所上市的美国医疗保健公司，拥有专注的产品组合、国际分销以及以投资组合优化而非积极扩大范围为中心的战略。（[avanos.com](https://avanos.com/news/avanos-medical-inc-announces-agreement-to-acquire-diros-technology-inc/?utm_source=openai)）
